News
GSK shares fell more than 6% on Friday to the bottom of Britain's blue-chip index after a U.S. FDA advisory panel recommended ...
In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...
The panelists flagged safety concerns with Blenrep and GSK’s failure to optimize its dosing regimen for the antibody-drug ...
The panel expressed concerns about the proposed doses of Blenrep (belantamab mafodotin) in GSK's marketing application, ...
The Swedish defense company posted better-than-expected earnings and [raised its annual sales guidance]( ...
Administering Shingrix previously required combining a lyophilised antigen with a liquid adjuvant from two separate vials.
With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities ...
On a quest to bring its multiple myeloma antibody-drug conjugate (ADC) Blenrep back to the U.S. | Members of the FDA's Oncologic Drugs Advisory Committee voiced concerns with ocular toxicity side ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback